homepage1

Affinity 2007 Conference
NYU Kimmel Center, New York, NY
July 8 - 12, 2007

Program and Speaker Biographies (as of June 30, 2007)

Sunday, July 8, 2007 Affinity 2007 Welcoming Reception (5 pm)
Introduction 6:30 pm to 6:45 pm	George Ehrlich, Hoffmann - La Roche, Nutley, NJ
Keynote Lecture 6:45 pm to 7:45 pm	A Human Protein Atlas Based on Affinity Proteomics Mathias Uhlén Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden
Monday, July 9, 2007
Opening Ceremonies 8:45 am to 9:00 am	Richard Willson, University of Houston, Houston, TX
Chairman Introduction 9:00 am to 9:15 am	Session 1: Affinity: Past, Present and Future Mathias Uhlén, Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden
101 9:15 am - 10:00 am	My Life with Affinity: Essentials of Biorecognition and its Application Meir Wilchek Department of Biological Chemistry, Weizmann Institute of Science, Rehovot, Israel
102 10:00 am to 10:30 am	Monolith Supports with Affinity and Pseudo Affinity Ligands for Superfast Purification of Biomolecules M. A. Vijayalakshmi^1,2 ¹Laboratoire d'Interactions Moléculaires et de Technologie de Séparation (LIMTech.S), Centre de Recherche de Royallieu, BP 20.529, 60205 Compiègne Cedex, France ²Center for BioSeparations Technology, VIT University, Vellore, 632014, India
Break 10:30 am to 10:50 am	Coffee/Posters/Exhibits
103 10:50 am to 11:20 am	Immunodepletion - What's Beneath the Tip of the Plasma Proteome Iceberg? Mark S. Baker^1,2, Alamgir Khan¹, Wai-Kei Shum², Sock-Hwee Tan², Veronika Polaskova² and Amit Kapur² ¹Australian Proteome Analysis Facility Ltd (APAF) ²Dept. of Chemistry and Biomolecular Sciences, Macquarie University, 2109. Sydney, Australia
104 11:20 am to 12:00 pm	The NCI’s Clinical Proteomic Technology Initiative for Cancer - The Reagent Resource Core Adam Michael Clark National Cancer Institute, Office of Technology and Industrial Relations, Bethesda MD
Lunch/Workshop 12:00 pm to 1:30 pm	Flexible Formats for Characterizing and Screening Protein-Protein Interactions using Bio Layer Interferometry on the Octet System Matthew Kirtley ForteBio, Inc. Menlo Park, CA
Chairman Introduction 1:30 pm to 1:45 pm	Session 2: Advances in Affinity Technologies Lars Hagel, GE Healthcare, Uppsala, Sweden
201 1:45 pm to 2:30 pm	Evolution of Industrial Affinity in Biopharmaceutical Production Duncan Low Process Development, Amgen, Inc., Thousand Oaks, CA
202 2:30 pm to 3:00 pm	Efficiency Improvements in the Discovery and Development of Novel Antibody Format and Protein-Based Biotherapeutics Using CaptureSelect® Affinity Ligands and Yeast Display Discovery Tools Hendrik Adams and Pim Hermans BAC bv (The BioAffinity Company), Huizerstraatweg 28, 1411 GP Naarden, Naarden, The Netherlands
Break 3:00 pm to 3:20 pm	Coffee/Posters/Exhibits
203 3:20 pm to 3:50 pm	Generation of Fully Human Antibodies Derived from Fab-on-phage Display Libraries. Rapid Kinetic-based Screening of Fab Fragments for Lead Identification Marc Vanhove Dyax s.a., Boulevard du Rectorat 27B, Building 22, B-4000 Liege (Sart-Tilman), Belgium
204 3:50 pm to 4:20 pm	Novel Approaches to Affinity Screening Enrique Carredano, Katarina Öberg, Tryggve Bergander, Lena Kärf, Charlotte Brink, Kristina Nilsson-Valimaa, Katarina Stenklo, Jan Bergström, Carina Engstrand, Åsa Dahlstedt-Hagman, Niklas Pettersson, Mats Nilsson, Nils Stafström, Karol Lacki, Bo-Lennart Johansson, Jean-Luc Maloisel GE Healthcare Biosciences AB, Uppsala, Sweden
Award Program 4:30 pm to 6:00 pm	Roche Younger Investigators A. Cecilia A. Roque, Centro de Química Fina e Biotecnologia, Universidade Nova de Lisboa, Caparica, Portugal 4:35 - 4:50 Development of HIC Media Useful for Isolation of Proteins Carrying Single Amino Acid Substitutions *Kristian Becker, Elisabeth Hallgren, Enrique Carredano, Ronnie Palmgren and Leif Bülow** Department of Pure and Applied Biochemistry, Centre for Chemistry and Chemical Engineering, Lund University Lund, Sweden GE Healthcare Bio-Sciences AB, Uppsala, Sweden 4:50 - 5:05 Development of New OMNiMIPs (One Monomer Molecularly Imprinted Polymers)* Jason LeJeune and David Spivak Department of Chemistry, Lousiana State University, Baton Rouge, LA 5:05 - 5:20 Novel Affinity Ligands for the Purification of Antibody Fragments Jonathan M. Haigh, Christopher R. Lowe Institute of Biotechnology, University of Cambridge, Cambridge, UK 5:20 - 5:40 Conformational Flexibility and Kinetic Complexity in Antigen-antibody Interactions Katerina Kourentzi, Mohan Srinivasan, Sandra J. Smith-Gill and Richard C. Willson Department of Chemical and Biomolecular Engineering, University of Houston, Houston, TX USA 5:40 - 6:00 Molecular Imprinted Polymers for Selective Protein Adsorption by Miniemulsion Polymerization Marc Herold, Klaus Niedergall, Melanie Dettling, Yunxiao Wang, Guenter Tovar Fraunhofer-Institute for Interfacial Engineering and Biotechnology & Institute for Interfacial Engineering, University of Stuttgart, Stuttgart, Germany
Day Break 6:00 pm to 8:00 pm	ISMR Council Meeting/Posters/Exhibits
Tuesday, July 10, 2007
Chairman Introduction 8:45 am to 9:00 am	Session 3: New Developments in Chromatography Juan A. Asenjo, Department of Chemical Engineering and Biotechnology, University of Chile, Santiago, Chile
301 9:00 am to 9:45 am	Mathematical Modeling of Elution Curves for a Protein Mixture in Chromatography Applied to the Optimal Selection of Operating Conditions J. A. Asenjo and B.A. Andrews Department of Chemical Engineering and Biotechnology, University of Chile, Santiago, Chile
302 9:45 - 10:15 am	Affinity Interaction under Chaotropic Conditions Rainer Hahn^1,2, Waltraud Kaar², Barbara Kanatschnig¹, Sabine Geinstetter¹, Karin Ahrer^1,2 and Alois Jungbauer^1,2 ¹Austrian Center of Biopharmaceutical Technology, Muthgasse 18, 1190 Vienna, Austria ²Department of Biotechnology, University of Natural Resources and Applied Life Sciences, Vienna, Muthgasse 18, 1190 Vienna, Austria
Break 10:15 am to 10:35 am	Coffee/Posters/Exhibits
303 10:35 am to 11:05 am	ImmunoAffinity Capillary Electrophoresis for the Identification and Characterization of Toxic Biomarkers Norberto A. Guzman Johnson and Johnson Pharmaceutical R&D, Global Preclinical Division, Raritan, NJ
304 11:05 am to 11:35 am	Biacore Applications for Effective Bio-therapeutic Development Brian Lang¹ and Fredrik Sundberg² ¹Biacore, Inc. part of GE Healthcare, 800 Centennial Ave., Piscataway, NJ 08854 ²GE Healthcare Life Sciences, Rapsgatan 7, 75450 Uppsala, Sweden
Lunch/Workshop 11:45 am to 1:15 pm	Success Story of MabSelect Victor Bornsztejn GE Healthcare, 800 Centennial Ave., Piscataway, NJ 08854
Poster/Exhibitor Session 1:15 pm to 2:15 pm	Please stand by your poster/exhibit
Chairman Introduction 2:15 pm to 2:30 pm	Session 4: Nano/Bio/Materials Richard Willson, University of Houston, Houston TX
Pierce Award Lecture 2:30 pm to 3:15 pm	Molecular Recognition of Proteins on Surfaces and the Development of Critical Hydrophobicity HIC Herbert P. Jennissen Institut für physiologsiche Chemie, Universität-Duisburg-Essen, Hufelandstr. 55, D-45122 Essen, Germany
401 3:15 pm to 3:45 pm	Analyte-Responsive Retro-reflectors for Biochemical Assays and Diagnostics P. Ruchhoeft, K. Han, A. Ruiz, V. Parekh, W. Xu, D. Litvinov, and S. Chellam University of Houston, Houston, TX USA 77204
Break 3:45 pm to 4:05 pm	Coffee/Posters/Exhibits
402 4:05 pm to 4:35 pm	Gold Nanorod Substrates for Localized Surface Plasmon Resonance Sensing Jason H. Hafner, Kathryn M. Mayer, Seunghyun Lee, Hongwei Liao, Betty C. Rostro, Peter T. Scully Department of Physics & Astronomy, Department of Chemistry, Rice University, Houston, TX USA 77005
403 4:35 pm to 5:05 pm	Discovery and Development of OMNiMIPs: One MoNomer Molecularly Imprinted Polymers David Spivak Department of Chemistry, Louisiana State University, Baton Rouge, LA
Panel Discussion 5:05 pm to 6:00 pm	Trends in Label-free Interaction Analysis Ashique Rafique, Regeneron Pharmaceuticals, Tarrytown, NY Matthew Kirtley (ForteBio), Brian Lang (GE Healthcare), Voula Kodoyianni (GWC Technologies)
Day Break 6:00 pm to 8:00 pm	Posters/Exhibits/Dinner on your own
Wednesday, July 11, 2007
Chairman Introduction 8:45 am to 9:00 am	Session 5: Insights into Intra- and Inter- Molecular Recognition M.A.Vijayalakshmi, CBST, VIT University, TamilNadu, India
501 9:00 am to 9:45 am	Self-Assembly of Soft Molecular Networks: Crystal Design and Curvature Michael Ward Molecular Design Institute, Dept. of Chemistry, New York University, New York, NY
502 9:45 - 10:15 am	Molecular Recognition of Foreign Sequences in Engineered 5S Ribosomal RNA Xing Zhang¹, Ajish S. R. Potty², George W. Jackson², George E. Fox¹, and Richard C. Willson^{1, 2} Department of Biology and Biochemistry¹ and Department of Chemical Engineering², University of Houston
Break 10:15 am to 10:35 am	Coffee/Posters/Exhibits
503 10:35 am to 11:05 am	Small-molecule-mediated Rescue of Protein Function by an Inducible Proteolytic Shunt Matthew Pratt and Tom Muir Laboratory of Synthetic Protein Chemistry, The Rockefeller University, 1230 York Avenue, New York, NY 10021
Social Event 11:05 am to 1:30 pm	Walking Tour of the Village featuring Arthur Marks Posters/Exhibits/Lunch on your own
Chairman Introduction 1:30 pm to 1:45 pm	Session 6: Protein Interactions In and On Cells Irwin Chaiken, Drexel University, Philadelphia, PA
601 1:45 pm to 2:30 pm	Dynamic Visualization of Signaling Activities in Living Cells Jin Zhang Depts. Pharmacology/Molecular Sciences and Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD
602 2:30 pm to 3:00 pm	Structure and Function of Eukaryotic RNA Exosomes C.D. Lima, Q. Liu, J.C. Greimann Program in Structural Biology, Sloan-Kettering Institute, New York, NY 10021 USA
Break 3:00 pm to 3:20 pm	Coffee/Posters/Exhibits
603 3:20 pm to 3:50 pm	Electrophoretic Fingerprinting of HIV-1 Cell Interaction: a Novel Tool for Development of Charge-Based Strategies Fairhurst, D.¹, Rowell, R.², Monahan, I.³, Stieh, D.³, McNeil-Watson, F.⁴, Morfesis, A.⁴, Romano, J.¹, Shattock, RJ.³ and M. Mitchnick⁵ ¹International Partnership for Microbicides, Silver Spring, USA, ²University of Massachusetts, Amherst, USA, ³St. Georges Hospital Medical School, London, UK, ⁴Malvern Instruments Ltd., Malvern, UK, ⁵Particle Sciences Inc., Bethlehem, USA
Session 6 Overview 3:50 pm - 4:20 pm	Irwin Chaiken, Drexel University, Philadelphia, PA
Poster/Exhibitor Session 4:20 pm to 5:20 pm	Please stand by your poster/exhibit
Social Event 6:15 pm	Gala Dinner Cruise on New York Harbor
Thursday, July 12, 2007
Chairman Introduction 8:45 am to 9:00 am	Session 7: Viruses and Vaccines Daniel Malamud, New York University Dental Center, New York, NY
701 9:00 am to 9:45 am	Ligand Recognition and Plasticity in HIV Envelope Glycoprotein gp120 Wayne A. Hendrickson^1,2, Hui Xie^2,3, Anil Korkut², Danny Ng⁴ and Amos B. Smith, III⁴ ¹Howard Hughes Medical Institute, ²Department of Biochemistry and Molecular Biophysics, and ³Department of Pharmacology, Columbia University, New York, NY 10032 USA ⁴Department of Chemistry, University of Pennsylvania, Philadelphia, PA 19104 USA
702 9:45 - 10:30 am	The Role of Antibodies in Preventing and Treating HIV Infection Susan Zolla-Pazner New York VA and NYU Medical Centers, New York, NY
Break 10:30 am to 10:50 am	Coffee/Posters/Exhibits
703 10:50 am to 11:20 am	Biomolecule Recognition in Piezoelectric Immunosensors: Application of Piezoimmunosensors for Detection of HIV1 Virion Infectivity Factor Guilherme N.M. Ferreira¹*, João M. Encarnação¹, Luis Rosa¹, Rogério Rodrigues¹, Luisa Pedro¹, Frederico Aires da Silva², João Gonçalves² ¹IBB-Institute for Biotechnology and Bioengineering, Centro de Biomedicina Molecular e Estrutural, Universidade do Algarve, 8000 Faro, Portugal ²URIA-Centro de Patógenese Molecular, Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal
704 11:20 am to 11:50 am	Interaction of gp340, a Glycoprotein in the Innate Immune System, with HIV-1 env Daniel Malamud New York University Dental Center, New York, NY
ISMR General Meeting 11:50 am to 12:15 pm	Presidential Announcements
Lunch Break 12:15 am to 1:15 pm	Posters/Exhibits/Lunch on your own
Chairman Introduction 1:15 pm to 1:30 pm	Session 8: Drug Discovery and Diagnostics Waseem Malick and Hitesh Chokshi, Hoffmann - La Roche, Nutley NJ
801 1:30 pm to 2:15 pm	The Economics of Personalized Medicine: Optimizing Incentives for Innovation M. J. Finley Austin Hoffmann - La Roche, Basel, Switzerland and Nutley, NJ
802 2:15 pm to 2:45 pm	Biomimetic and Supramolecular Scaffolds for Multivalent Display Kent Kirshenbaum Department of Chemistry, New York University New York, NY
803 2:45 pm to 3:15 pm	Designing for Success: The Generation of Useful Leads with Small Molecule Libraries Robert A. Goodnow Jr. Discovery Chemistry, Hoffmann-La Roche, Inc., Nutley, NJ
804 3:15 pm to 4:00 pm	Cancer Chemotherapy with an FDA Approved Transition State Analog Enzyme Binder Ronald Breslow Department of Chemistry, Columbia University, New York, NY
Closing Remarks 4:00 pm to 4:30 pm	Affinity 2009: the 18th Biennial Meeting of the International Society for Molecular Recognition Hordur Filippusson, Organizer and Gidi Fleminger, ISMR President Elect Summer 2009 Reykajvik, Iceland

Speaker Biographies

Mathias Uhlén

Mathias Uhlén is Professor of Microbiology at the Royal Institute of Technology (KTH), Stockholm, Sweden. Dr Uhlén is member of the Royal Swedish Academy of Engineering Science (IVA), the Royal Swedish Academy of Science (KVA) and the European Molecular Biology Organization (EMBO). He is Vice-President of the European Proteomics Association (EuPA) and member of the Human Proteome Organization (HUPO) council. He was Vice-President of the Royal Institute of Technology (KTH), responsible for external relations, from 1999 to 2001 and he was the chairman of the Swedish Biochemical and Molecular Biology Society (SFMB) from 1994 to 1999. Dr Uhlén has more than 280 publications in bioscience with the focus on the development and use of affinity reagents in biotechnology and biomedicine.

In the early eighties, Dr Uhlén cloned and characterized staphylococcal protein A, which is now used extensively for purification of antibodies both in diagnostics and therapy. He showed in 1983, for the first time, the principle of affinity capture of fusion proteins. The use of affinity tags for purification of recombinant proteins are now widely used in bioscience. In the late eighties, Uhlén published the use of magnetic micro spheres with streptavidin for automated solid phase applications. Such laboratory systems based on streptavidin beads are at present frequently used both in research and diagnostics. In the 90’ies, his group described a new principle for affinity reagents, called Affibodies, and showed their use as research tool and recently as potential cancer therapeutics. Uhlen and colleagues also developed a new strategy for DNA analysis called Pyrosequencing, a method that has recently been further developed by a US company (454) into a highly parallelized sequencing instrument.

Dr Uhlén is currently working on the Human Protein Atlas (HPA) program, with the aim to systematically map the human proteome. In October 2006, version 2.0 of the Protein Atlas was published (www.proteinatlas.org) with more than 1.2 million high-resolution images representing 1,359 human proteins. He has founded several companies, including Pyrosequencing AB (Biotage AB), Affibody AB, SweTreeGenomics AB, Magnetic Biosolutions AB, Creative Peptides AB and Atlas Antibodies AB. He has received numerous awards, including The Svedberg prize in 1992, the Göran Gustavsson prize in 1993, the gold medal of the Royal Swedish Academy of Engineering Sciences in 2004, the Most Noble Order of the Seraphim - the Order of His Majesty the King in 2004, the Jerker Porath award and the Akzo Nobel Award in 2005 and the HUPO Distinguished Achievement Award in 2006.

Meir Wilchek

Professor Meir Wilchek has always worked in the interface between organic chemistry and biology, played a pivotal role in the use of the principles of organic chemistry (known today and chemical genetics) for the understanding of biological processes and the establishment of the modern-day concept of biorecognition and its development for the myriads of applications in the various fields of modern biology. This concept and the associated processes, which Meir Wilchek has designed, have had a profound effect on research, industry, medicine, molecular biology, and, consequently, on the human condition in general. In view of the inherent clinical and medical implications of Dr. Wilchek's discoveries, it should come as no surprise that among the list of prizes he has already received, which include the prestigious Wolf Prize, the Israel Prize, and the Pierce Prize, he was elected to the Institute of Medicine of the National Academy of Science, USA.

Meir Wilchek's studies have been directed towards the understanding and application of the biorecognition phenomenon using chemical methods, and his major contributions have been directed in four different but related aspects: namely, affinity chromatography, affinity labeling, affinity therapy and avidin-biotin technology. Historically, the contribution for which he is best known and for which he has received the most internationally acclaimed awards and honors is the field of affinity chromatography and the avidin-biotin system. In addition, his contributions to the other above-mentioned fields have been of critical scientific impact. In all the above fields, in which he was among the founders, he had to device chemical methods to immobilize, derivatize biological active molecules, such as protein, nucleic acid and even whole cells. All these methods are widely used all over the world.

Adam Michael Clark

Dr. Clark serves as the Program Officer for the Clinical Proteomic Technologies Initiative for Cancer (CPTI) and the Mouse Proteomic Technologies Initiative at the National Cancer Institute. In this role, Dr. Clark oversees the management and operations of the various programs within the initiatives and works to integrate the developing proteomic technologies for application in clinical settings. He also narrates the Clinical Proteomic Technologies tutorial on the CPTI website. His work at the NCI is focused on improving clinical research technologies so that molecular-based medicine approaches can be applied in a clinical setting to make personalized medicine and targeted therapeutics common in medical practice.

Dr. Clark has a background in both medical science research and health policy. Dr. Clark has served as both a researcher and a program administrator for the National Cancer Institute. In addition to his work with the CPTI, Dr. Clark served as the Life Science Policy Analyst at the White House's Office of Science and Technology Policy working on a variety of issues including overweight/obesity health issues and strategies, stem cell research, and cancer imaging technologies. Dr. Clark also served as the science policy advisor for the Deputy Chief of Staff in the Office of the Secretary, Department of Health and Human Services working on several key projects in the Department including the 2005 Dietary Guidelines for Americans. Dr. Clark returned to the NCI Office of Technology and Industrial Relations in 2005.

Dr. Clark has a Ph.D. in Environmental Health from the University of Cincinnati College of Medicine with an emphasis on gene-environment interactions in disease onset and targeted treatment. Dr. Clark's research experience focused on alterations of signal transduction pathways in tumorigenesis. He was enrolled in the Graduate Partnership Program at the National Institutes of Health and was a 2002 recipient of the Cancer Research Training Award from the National Cancer Institute where he completed his graduate studies and postdoctoral work.

Lars Hagel

Lars Hagel is Director of External R&D Collaborations at GE Healthcare Bio-Sciences AB, Uppsala, Sweden and associate professor in analytical chemistry at Uppsala University. He joined Pharmacia in the mid 70'íes and has held scientific and management positions within the R&D departments of Pharmacia Biotech, Amersham Pharmacia Biotech and now GE Healthcare. Lars has authored approximately 30 papers, chapters and textbooks related to chromatography, and in particular to gel filtration. His latest contribution is as co-author to the second edition of Process Chromatography Handbook which will be released in the autumn of 2007. Lars is frequently engaged in the steering of joint efforts and strategic initiatives between academia, industry and society in Sweden. He arranged and was the meeting chairman for Affinity 2005 held in Uppsala, August 2005.

Duncan Low

Duncan Low, Scientific Executive Director, joined the Process Development Department at Amgen in 2003, where he leads cross-functional teams for technology evaluation, technology development and Process Analytical Technology. He is a member of the ISPE Executive Committee for PAT and chairs the ASTM E55.01 subcommittee. Prior to joining Amgen he held senior positions at Millipore and Pharmacia Biotech. He has extensive experience of the tools currently in use in upstream and downstream processing and has worked closely with applications development throughout the industry. He has an M.A. in biochemistry from the University of Cambridge and a Ph.D. in microbiology from the University of Glasgow.

Hendrik Adams

Prior to joining The Bio Affinity Company (BAC) as Ligand Discovery Scientist, Hendrik Adams was a postdoctoral scientist in the Cellular Architecture & Dynamics group of Utrecht University (The Netherlands). In this group, he carried out research for the application of llama antibodies in medical devices. Previously, he was a postdoctoral scientist within a Marie Curie Research Training Network funded by the European Union. In that position, he studied the iron uptake in the opportunistic pathogen Pseudomonas aeruginosa in the department of Receptors and Membrane Proteins at the University of Strasbourg (France). He received his Ph.D. degree in the field of Molecular Microbiology from the Utrecht University.

Mark S. Baker

Received his BSc Hons 1 in 1981 & PhD in 1985Macquarie University and undertook postdoctoral studies at Monash University, John Curtin School of Medical Research and Howard Hughes Medical Research Institute University of Michigan. Mark is currently the Chief Executive Officer of a Major National Research Facility called the “Australian Proteome Analysis Facility” and he is also Professor of Proteomics, Dept. Chemistry & Biomolecular Sciences, Macquarie University.

Mark’s previous industry experience is in the development of new biochip platforms (through LumiCyte California, USA). He was the founder of the Gynaecological Cancer Research Centre, Royal Women’s Hospital, Melbourne, is a Council Member of HUPO and Asia Oceania HUPO as well as Secretary of the Australasian Proteomics Society. Mark is currently a member of the Science Industry Action Agenda Leader’s Group. He won the 1994 Sports Medicine Australia Order of Fellows, the 1991 Howard Florey Young Investigator Medal and the 1988 & 1990 International Young Investigator Awards from the Society for Free Radical Research. He has over 80 publications, 3 patents, has trained ~20 PhD students and ~30 BSc(Hons)/BBiotech students.

Mark’s interests are in biomarker discovery, proteomic technologies, research commercialisation, building the Australian biotech sector and Rugby. He holds grants with proteomics industry leaders (eg. GE Healthcare, QIAGEN, Applied Biosystems) and has most recently developed novel immunodepletion strategies using chicken eggs.

Monday, July 9, 2007

Tuesday, July 10, 2007

Wednesday, July 11, 2007

Thursday, July 12, 2007